An anticancer agent such as gefitinib, a tyrosine kinase inhibitor [10] inhibiting receptor tyrosine kinase activity of EGFR, shows good efficacy for patients with EGFR mutant lung cancers, but drug resistance and metastatic properties can occur [8,11]. This evidence concerns the gene EGFR and lung cancer.